We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Lupin’s MEK inhibitor compound is planned for clinical development in combination with Boehringer Ingelheim’s KRAS inhibitor pipeline to address KRAS-driven cancers.
When Amgen’s cancer-killing virus Imlygic—also known as T-Vec—was approved by the FDA in late 2015, experts expected it would work best in combination strategies for melanoma.....